Steven Oh


As Deputy Director, Dr. Steven Oh leads the division that reviews the product and CMC information for cell and gene therapy products, tissue-engineered products, combination products, and related point-of-care devices submitted to CBER, FDA. He actively participates in developing CBER regulatory policies that involve cross-cutting science and emerging technologies in regenerative medicine advanced therapies. He also participates in efforts to help develop standards and to promote global regulatory convergence in manufacturing and testing cellular, tissue-engineered, and gene therapy products. Before joining FDA in 2007, Dr. Oh served on the faculty of Tufts University School of Medicine. He was trained as a cell biologist and biochemist at Massachusetts Institute of Technology, Johns Hopkins University School of Medicine, and the University of Michigan.